Zobrazeno 1 - 10
of 368
pro vyhledávání: '"pharmaceutical regulation"'
Autor:
Sandeep Bhupendra Maharaj, Darren Dookeeram, Roger Hosein, Kelvin Ramkissoon, Amrica Ramdass, Darleen Y. Franco, Shalini Pooransingh
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
This article seeks to highlight an aspect of the illegal pharmaceutical trade in the Caribbean. With the advent of COVID-19 there has been a shortage of a number of drugs in the formal sector. This is largely due to restrictions on foreign exchange,
Externí odkaz:
https://doaj.org/article/6bb4bcb1425e4b44bc311edefca3950e
Publikováno v:
Frontiers in Medical Technology, Vol 6 (2024)
The regulation and use of herbal medicines is a topic of debate due to concerns about their quality, safety, and efficacy. EU Directive 2004/24/EC on Herbal Medicinal Products was a significant step towards establishing a regulatory framework for her
Externí odkaz:
https://doaj.org/article/69d1dbb73c2e4876a21bb1fb6dd14c2a
Publikováno v:
Journal of Health Organization and Management, 2021, Vol. 35, Issue 8, pp. 987-1007.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/JHOM-08-2020-0344
Autor:
Krasimira Valcheva
Publikováno v:
Journal of IMAB, Vol 27, Iss 1, Pp 3598-3603 (2021)
In the last few decades, the problem with falsified medicine became a global threat that accounts for millions of human lives and billions of financial loses for the national health authorities and pharmaceutical industry. Different measures were dev
Externí odkaz:
https://doaj.org/article/8193219f3d5641d1933d7ca7aeb8b06d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Joshua D. Wallach, Anita T. Luxkaranayagam, Sanket S. Dhruva, Jennifer E. Miller, Joseph S. Ross
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background Postmarketing commitments are clinical studies that pharmaceutical companies agree to conduct at the time of FDA approval, but which are not required by statute or regulation. As FDA increasingly adopts a lifecycle evaluation proc
Externí odkaz:
https://doaj.org/article/ff4fd1e9198f4a8b969474f886ee7fd3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Takuya Onoda
Publikováno v:
Journal of European Public Policy
Journal of European Public Policy, 2023, pp.1-22. ⟨10.1080/13501763.2023.2176909⟩
Journal of European Public Policy, 2023, pp.1-22. ⟨10.1080/13501763.2023.2176909⟩
International audience; Both proponents and critics of the regulatory state thesis view the creation of non-majoritarian institutions, such as independent regulatory agencies, as a process of 'depoliticisation'. This article problematises this assump
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aff733ee7172c1c35de8adf394d41e6
https://doi.org/10.1080/13501763.2023.2176909
https://doi.org/10.1080/13501763.2023.2176909
Publikováno v:
Canadian Journal of Bioethics, Vol 3, Iss 1 (2020)
Drug regulatory bodies aim to ensure that patients have access to safe and effective drugs; however, no matter the quality of pre-licensure studies, uncertainty will remain regarding the safety and effectiveness of newly approved drugs until a large
Externí odkaz:
https://doaj.org/article/b3e5780b291e4d24a7770f580ec89f1b